Frunevetmab |
![]() Last updated: 15/09/2025 |
![]() |
(Not known by any other names) |
|
![]() |
|
A canine immunoglobulin G2 monoclonal antibody for pain management | |
---|---|---|
|
Pain from osteoarthritis | |
|
Cats |
Approval status |
|
Approved - usually available as a prescription only medicine to be authorised by a veterinarian (POM-V) | |
---|---|---|
|
Approved |
Chemical structure |
|
None | |
---|---|---|
|
C₆₄₅₈H₉₉₇₂N₁₇₄₀O₂₀₁₄S₄₄ | |
|
- | |
|
- | |
|
- | |
|
- | |
|
No |
General status |
|
Analgesic, Medicinal drug | |
---|---|---|
|
Protein-based drug | |
|
- | |
|
- | |
|
Natural | |
|
Targets Nerve Growth Factor which reduces the hyperalgesis response associated with osteoarthritis and so helps manage the associated pain | |
|
[Nerve growth factor, Agonist] | |
|
1708936-80-4 | |
|
- | |
|
- | |
|
- | |
|
- | |
|
Opiods: Other analgesics and antipyretics | |
|
QN02BG90 | |
|
No | |
|
- | |
|
14600 | |
|
frunevetmab | |
|
- | |
|
- | |
|
- | |
|
- | |
|
- | |
|
- | |
|
Colourless to pale yellow, slightly opalescant liquid | |
|
Commercial |
|
|
|||
---|---|---|---|---|
|
Current | |||
|
2021, approved EU; 2022, approved USA | |||
|
|
|||
|
|
|||
|
Usually administered via subcutaneous injection | |||
|
The production of frunevetmab follows a highly specialised biotechnological process typical of therapeutic antibody manufacturing. It begins with the genetic engineering of mammalian cell lines, often Chinese Hamster Ovary (CHO) cells, which are transfected with DNA encoding the feline-specific immunoglobulin G (IgG) sequence that binds NGF. These cells are cultured in large-scale bioreactors under sterile, nutrient-rich conditions to express the antibody. After sufficient growth, the culture medium is harvested and the antibody is purified using affinity chromatography, typically with protein A columns, followed by polishing steps like ion-exchange and size-exclusion chromatography to ensure purity and structural integrity. | |||
|
As a ballpark figure, the GHG emissions per gram of frunevetmab could conservatively range from 100 to 300 kg CO₂e, depending on the facility’s energy mix and efficiency. |
|
![]() |
|
|
|
|
||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
- | |||||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
No adverse impacts identified or anticipated |
Degradation |
|
|
|
|
||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | ||||||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
As this parameter is not normally measured directly, a surrogate measure is used: ‘Photochemical oxidative DT₅₀’. Where data is available, this can be found in the Fate Indices section below. | ||||||||||
|
- |
Soil adsorption and mobility |
|
|
|
|
||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
|
- | - | - | |||||||
|
- | ||||||||||
|
- | ||||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
- | ||||||||||
|
- | ||||||||||
|
- |
Fate indices |
|
|
|
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
- | - | - | ||||||||||||||||||||||||||
|
|
- | - | - | |||||||||||||||||||||||||
|
- | - |
Known metabolites |
None
|
![]() |
Terrestrial ecotoxicology |
|
|
|
|
||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | |||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | ||||||||||
|
|
- | - | - | |||||||
- | |||||||||||
|
- | - | - | ||||||||
- | |||||||||||
|
|
- | - | - | |||||||
|
- | - | - | ||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
|
- | - | - | |||||||
|
- | ||||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - |
Aquatic ecotoxicology |
|
|
|
|
||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | - | - |
|
- | - | - | |||
|
- | - | - |
|
![]() |
General |
|
|
|
|
||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
- | - | - | ||||||||
|
|
- | |||||||||
|
- | ||||||||||
|
Eliminated through protein degradation pathways | Q3 Q = Miscellaneous data from online sources 3 = Unverified data of known source |
- |
Health issues |
|
|
||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
No information available |
Handling issues |
|
|
|||
---|---|---|---|---|
|
May emit irritant fumes if heated to decomposition | |||
|
- | |||
|
- | |||
|
Not registered | |||
|
- | |||
|
Shelf life is around 2 yrs. Protect from light. Do not freeze. |
|
![]() |
|
|
||
---|---|---|---|
|
frunevetmab | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- | ||
|
- |
Record last updated: | 15/09/2025 |
Contact: | aeru@herts.ac.uk |
Please cite as: | Lewis, K.A., Tzilivakis, J., Warner, D. and Green, A. (2016) An international database for pesticide risk assessments and management. Human and Ecological Risk Assessment: An International Journal, 22(4), 1050-1064. DOI: 10.1080/10807039.2015.1133242 |